| Company Name: |
Biolab Reagents |
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
|
| | Trevogrumab Basic information |
| Product Name: | Trevogrumab | | Synonyms: | Trevogrumab;Research Grade Trevogrumab (DHA30602);Research Grade Trevogrumab;Trevogrumab (anti-GDF8) | | CAS: | 1429201-24-0 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Trevogrumab Structure]() |
| | Trevogrumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Trevogrumab Usage And Synthesis |
| Uses | Trevogrumab (REGN-1033) is a monoclonal antibody targeting GDF8 (growth differentiation factor 8, also known as myostatin). Trevogrumab is used in research on muscle wasting conditions, including disuse atrophy, chronic diseases, and changes in food and nutrient intake[1][2][3]. | | in vivo | Trevogrumab (10 mg/kg, s.c., twice a week for 4 weeks) significantly increases muscle mass and strength in CB17-SCID and C57BL/6 mice[3]. | Animal Model: | CB17-SCID and C57BL/6 mice[3] | | Dosage: | 0.1-30 mg/kg | | Administration: | Subcutaneous injection (s.c.), twice a week for 4 weeks | | Result: | Significantly increased muscle weight (~20%) in gastrocnemius (GA) and tibialis anterior (TA) muscles and increased muscle fiber area (~15%) in mice. |
| | References | [1] Masakazu Saitoh, et al. Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy. Volume2, Issue1,January 2017,Pages 1-10
[2] Mitra A, et al. The elusive role of myostatin signaling for muscle regeneration and maintenance of muscle and bone homeostasis. Osteoporos Sarcopenia. 2023 Mar;9(1):1-7. DOI:10.1016/j.afos.2023.03.008
[3] Latres E, et al. Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. Skelet Muscle. 2015 Oct 9;5:34. DOI:10.1186/s13395-015-0060-8 |
| | Trevogrumab Preparation Products And Raw materials |
|